SPAG5 and hepatocellular carcinoma: In addition, we increased SPAG5 expression in HCC cells by treating them with specific inhibitor of β-catenin, XAV-939 (Tankyrase 1/2 inhibitor), which selectively inhibits β-catenin-mediated transcription through promoting β-catenin degradation.